First potential immunization against RSV for healthy infants found highly effective in phase 3 trial
Nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomized, placebo-controlled ...